EUVIMEDEUVIMED entdecken
Open Access

Liraglutide administration improves hormonal/metabolic profile and reproductive features in women with HAIR-AN syndrome

S Livadas, I Androulakis, N Angelopoulos, A Lytras, F Papagiannopoulos, G Kassi

Endocrinology, Diabetes & Metabolism Case Reports · 04.06.2020 · 2020

DOI: 10.1530/edm-19-0150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism Case Reports, erschienen am 04.06.2020. Verfasst von S Livadas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Unit, Metropolitan Hospital, Athens, Greece. Die Arbeit wurde bisher 19-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HAIR-AN syndrome, the coexistence of Hirsutism, Insulin Resistance (IR) and Acanthosis Nigricans, constitutes a rare nosologic entity. It is characterized from clinical and biochemical hyperandrogenism accompanied with severe insulin resistance, chronic anovulation and metabolic abnormalities. Literally, HAIR-AN represents an extreme case of polycystic ovary syndrome (PCOS). In everyday practice, the management of HAIR-AN constitutes a therapeutic challenge with the available pharmaceutical agents. Specifically, the degree of IR cannot be significantly ameliorated with metformin administration, whereas oral contraceptives chronic administration is associated with worsening of metabolic profile. Liraglutide and exenatide, in combination with metformin, have been introduced in the management of significantly obese women with PCOS with satisfactory results. Based on this notion, we prescribed liraglutide in five women with HAIR-AN. In all participants a significant improvement regarding the degree of IR, fat depositions, androgen levels and the pattern of menstrual cycle was observed, with minimal weight loss. Furthermore, one woman became pregnant during liraglutide treatment giving birth to a healthy child. Accordingly, we conclude that liraglutide constitutes an effective alternative in the management of women with HAIR-AN. Learning points: HAIR-AN management is challenging and classic therapeutic regimens are ineffective. Literally HAIR-AN syndrome, the coexistence of Hirsutism, Insulin Resistance and Acanthosis Nigricans, represents an extreme case of polycystic ovary syndrome. In cases of HAIR-AN, liraglutide constitutes an effective and safe choice.

Schlagwörter

Stichwörter der Autor:innen

2020Acanthosis nigricansAcneAdultAmenorrhoeaAndrogensAndrostenedioneAnovulationFemaleGLP1 agonistsGlucose tolerance (oral)GreeceGynaecological endocrinologyGynaecologyHAIR-AN syndrome*

Autor:innen und Institutionen

  • Endocrine Unit, Metropolitan Hospital, Athens, Greece.
  • Novo-Nordisk, Athens, Greece.
  • Endocrine Unit, Alexandra Hospital, Athens, Greece.

Zitieren

APA

Livadas, S., Androulakis, I., Angelopoulos, N., Lytras, A., Papagiannopoulos, F., & Kassi, G. (2020). Liraglutide administration improves hormonal/metabolic profile and reproductive features in women with HAIR-AN syndrome. Endocrinology, Diabetes & Metabolism Case Reports, 2020. https://doi.org/10.1530/edm-19-0150

Vancouver

Livadas S, Androulakis I, Angelopoulos N, Lytras A, Papagiannopoulos F, Kassi G. Liraglutide administration improves hormonal/metabolic profile and reproductive features in women with HAIR-AN syndrome. Endocrinology, Diabetes & Metabolism Case Reports. 2020;2020. doi:10.1530/edm-19-0150

BibTeX
@article{Livadas2020,
  author = {Livadas, S and Androulakis, I and Angelopoulos, N and Lytras, A and Papagiannopoulos, F and Kassi, G},
  title = {Liraglutide administration improves hormonal/metabolic profile and reproductive features in women with HAIR-AN syndrome},
  journal = {Endocrinology, Diabetes & Metabolism Case Reports},
  year = {2020},
  volume = {2020},
  doi = {10.1530/edm-19-0150}
}
Kostenlos starten →